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OBJECTIVEdIn the U.K., people with diabetes are typically screened for retinopathy annu-
ally. However, diabetic retinopathy sometimes has a slow progression rate. We developed a
simulation model to predict the likely impact of screening patients with type 2 diabetes, who
have not been diagnosed with diabetic retinopathy, every 2 years rather than annually. We aimed
to assess whether or not such a policy would increase the proportion of patients who developed
retinopathy-mediated vision loss compared with the current policy, along with the potential cost
savings that could be achieved.
RESEARCHDESIGNANDMETHODSdWe developed a model that simulates the pro-
gression of retinopathy in type 2 diabetic patients, and the screening of these patients, to predict
rates of retinopathy-mediated vision loss. We populated the model with data obtained from
a National Health Service Foundation Trust. We generated comparative 15-year forecasts to
assess the differences between the current and proposed screening policies.
RESULTSdThe simulation model predicts that implementing a 2-year screening interval for
type 2 diabetic patients without evidence of diabetic retinopathy does not increase their risk of
vision loss. Furthermore, we predict that this policy could reduce screening costs by ;25%.
CONCLUSIONSdScreening people with type 2 diabetes, who have not yet developed ret-
inopathy, every 2 years, rather than annually, is a safe and cost-effective strategy. Our findings
support those of other studies, and we therefore recommend a review of the current National
Institute for Health and Clinical Excellence (NICE) guidelines for diabetic retinopathy screening
implemented in the U.K.
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D iabetic retinopathy is a serious com-plication for people with diabetesthat can lead to blindness or severe
vision loss (1). Although retinopathy can-
not be cured, its progression can be slowed
or halted, and laser treatment can prevent
visual loss if offered promptly at the pro-
liferative stage (2). Diabetic digital retinal
photography is an effective method of de-
tecting the onset of treatable retinopathy
(3). National Institute for Health and Clin-
ical Excellence (NICE) guidelines in the
U.K. currently recommend that people
with diabetes are screened for retinopathy
annually, or every 3–6 months for those
patients who have developed beyond
mild background retinopathy or who are
at higher risk of progression (4). This also
forms part of the National Screening
Committee’s policy of a national screen-
ing program for diabetes in the U.K. (5).
The development of retinopathy may
take decades (6), and the annual screening
of all diabetic patients may therefore incur
considerable cumulative health service cost
and patient inconvenience that, for some,
may be unjustified (7).With a significant in-
crease in diabetes incidence forecast in the
U.K. (8), it is imperative that screening
policies for diabetes complications are
cost-effective and practicable. It is there-
fore prudent to ask whether it would be
cost-effective and safe to screen diabetic
patients for retinopathy less frequently (7),
particularly in light ofmore recent evidence
that suggests an overall decline in the rates at
which people with diabetes are developing
vision-threatening retinopathy (9,10).
We undertook a collaborative project
with the Royal Devon and Exeter National
Health Service (NHS) Foundation Trust
(henceforth referred to simply as Royal
Devon and Exeter), which carries out an-
nual retinopathy screening for a population
of ;20,000 patients across Devon. Using
simulation modeling, we assessed the
potential impact of implementing a 2-year
retinopathy screening interval for those
patients without retinopathy and who
have type 2 diabetes. Diabetic retinopathy
may progress more quickly in patients
with type 1 diabetes (1,11–13), and al-
though it has been shown that less fre-
quent screening may be feasible for type 1
patients (14), we focus on the lower-risk
type 2 diabetic patient group in this study.
Previous studies have looked at the cost-
effectiveness of longer screening intervals
for diabetic retinopathy screening across
all patients in a population (7,15,16),
but we assessed an increased screening in-
terval solely for those patients who have
not yet been diagnosed with diabetic reti-
nopathy. These patients represent;40% of
the type 1 and type 2 diabetic population
screened by Royal Devon and Exeter, and
reductions in the frequency with which
they are screened could therefore lead to
large potential cost and resource savings.
RESEARCH DESIGN AND
METHODS
The retinopathy screening model
Simulation modeling is an operational
research technique that can be used to
predict the impact of specified changes to
a defined pathway, such as changes to the
screening policies for diabetic retinopathy
in this instance. By using existing data,
such as the incidence and progression
rates of diabetic retinopathy, we can con-
struct a model that simulates the progres-
sion of the disease and patient screening,
thereby allowing us to alter parameters to
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generate predictions on the impact of certain
changes.
The patient-oriented simulation tech-
nique (POST) is a well-regarded example
of a simulation model that has been used
to evaluate screening strategies for diabetic
retinopathy (1,11). POST simulates the
retinopathy progression and screening of
individual diabetic patients throughout
their lifetimes. We developed a new
model, retinopathy screening simulation
(ReSS), that builds upon POST, by placing
it within a modeling framework that ex-
plicitly models each patient separately, al-
lowing us to more easily model screening
and retinopathy progression. In ReSS,
each patient has a “state” that specifies
how far their retinopathy has progressed,
whether they have lost their vision, or
whether they have died. The progression
of their retinopathy is described using the
U.K. National Screening Committee grad-
ing system (5): R0 indicates no retinopathy,
and R1, R2, and R3 indicate background
diabetic retinopathy (BDR), preprolifera-
tive diabetic retinopathy (pre-PDR), and
PDR, respectively. We assume that a pa-
tient’s grade is determined by their “worst”
eye (the one that has the most advanced
development of retinopathy). A patient who
has lost their vision in at least one eye has a
state called “vision loss,” and a patient who
has died has a state called “death.”
In our model, patients are given a
baseline grade of retinopathy and an age.
No patients have lost their vision at the
start of the model. Time advances in incre-
ments of 1 day. Figure 1 summarizes the
patient-level processes in the model.
For every day that elapses in the model,
a patient in the model may die (which is
dependent upon their age and progression
of their retinopathy) or may progress to
the next stage of retinopathy. In addition, a
patient may have a screening or treatment
appointment scheduled on that day.
If a patient in the model is due to be
screened, they may or may not attend,
depending on their compliance. If they
do not attend, another appointment is
arranged. Patients who fail to attend three
consecutive appointments are contacted
by their general practitioner. If they do
not arrange another appointment after
this, they are removed from the model.
Patients in themodel who attend a screen-
ing appointment are screened for retinop-
athy using digital retinal photography (3),
which is carried out by retinal screening
graders. The probability that the test
provides a true positive or a true negative
is given by the test’s sensitivity and
specificity, respectively. If a patient re-
ceives a negative result, no further action
is taken, and their next screening appoint-
ment is arranged according to their risk. R0
and R1 patients are screened annually (ex-
cept in the proposed new policy, where R0
patients are screened every 2 years) and R2
patients are screened every 6 months, in
line with the minimum standards derived
from the NICE guidelines (4).
If a patient receives a positive result,
this is assessed by a secondary retinal
grader, such as the retinal screening service
manager, who checks the results of the
primary grader to maximize diagnostic
accuracy. If the secondary grader identifies
that the patient does not have retinopathy,
or they have stage R1 orR2 retinopathy, the
patient’s next screening appointment is ar-
ranged according to their disease progres-
sion. If the graders identify the patient as
having PDR (R3), treatment is given.
If a patient in themodel is to be treated,
then the treatment may or may not suc-
ceed. If the treatment does succeed, the
patient’s probability of developing vision
loss from state R3 is reduced. Either way,
for simplification, the patient does not at-
tend any further screening appointments.
Populating the retinopathy
screening model
When populating the retinopathy model
(ReSS), we considered two different sce-
narios: the 2S (or two-stream) scenario
represents the current world order, in
which patients are screened either an-
nually or every 6 months, and the 3S
(or three-stream) scenario represents the
proposed strategy of screening R0 pa-
tients every 2 years, rather than annually.
For simplification, we assume 1 year to be
365 days and 6 months to be 182 days.
Each scenario was simulated for 15 years
and replicated 10 times, with results aver-
aged over the replications.
Royal Devon and Exeter supplied an
anonymized patient dataset for the project,
which was comprised of those records
that could be cross-matched across both
the internal screening administration sys-
tem and the internal clinical database, to
provide all required data. This provided us
with 3,537 unique patient records and
33,810 unique screening appointments dat-
ing from 1991 to 2011, of which 2,201
patients were type 2 diabetic patients.
Patient records included patient sex,
date of diagnosis of diabetes, type of
diabetes, screening dates, and latest
screening grade. Appointment records
specified the date and time of the appoint-
ment, the patient’s age at the appointment,
whether or not the appointment was can-
celled and the reason for cancellation, and
the screening grade given as an outcome
of the appointment. Of the 3,537 patients,
57.6% were male and 40.9% were female.
The sex of 53 patients (1.5%) was not
specified.
Figure 1dPatient-level processes in ReSS model. This flowchart summarizes the process steps
that patients in the model follow.
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The Royal Devon and Exeter data
show that patients are 86% likely to attend
a screening appointment. If an appoint-
ment is missed, an alternative appoint-
ment is usually arranged within a few days,
but can be much longer if the patient has
to be fitted into a clinic at the hospital. As
such, the average time given by the Royal
Devon andExeter data is 93days. Although
this is not representative of common
shorter waits, we implement this figure in
the model as a “worst-case scenario.” We
used a diabetes incidence rate of 4.42/
1,000 person-years in the model as an ini-
tial estimate (17) and increased this by
4.1% of the initial incidence rate at the
end of each year (18). The initial simulated
diabetic patient population size was 5,000.
The ages of patients in themodel were
drawn directly from the patient data sup-
plied by Royal Devon and Exeter. Mortality
rates for patients in the model were based
on data from a 2005 study of mortality in
diabetic patients (19), which also included
a Cox proportional hazards model, from
which we estimated rate adjustments for
the various stages of retinopathy. Rates
were averaged across both sexes for each
age group and were converted to daily
mortality rates.
The R-grade distributions at baseline
in the model were taken from the first
screening grades on record for each type 2
diabetic patient in the Royal Devon and
Exeter data. Therefore, for patients within
the model, 54.9% started at R0, 37.6% at
R1, 4.9% at R2, and 2.6% at R3. This
compares to 73% at R0, 18% at R1, 2%
at moderate R2, and 0.5% at R3 in the
Liverpool Diabetic Eye Study (7). The
higher rates of background retinopathy
and above at baseline in the Royal Devon
and Exeter data may indicate an increased
risk of retinopathy in this population.
Sensitivity and specificity data for the
digital retinal photography screening test
were supplied by Royal Devon and Exeter
and are 98.86 and 99.52%, respectively.
They also provided an NHS cost figure of
£37 per screening episode, which is typ-
ical of screening units in the U.K. (cost
code C5-local Specialty Patient Type 41
[Community/Domiciliary]). These values
were used directly in the model. Positive
results are typically assessed within 1
week after the screening appointment,
but the dataset included data from a pe-
riod of historical backlogs; therefore, the
average across the dataset was 20 days. We
used a value of 20 days in the model to
represent a worst-case scenario. Grading
assessments (after initial grading) are
assumed to be 100% accurate, as they
are checked multiple times by other grad-
ers. If a patient in the model is diagnosed
with PDR (R3), they are sent for treatment
14 days later, which is the minimum re-
quirement according to NHS quality as-
surance standards (20). A patient’s laser
photocoagulation treatment occurs as a
single episode in the model, for the pur-
poses of simplification, and is 84% likely
to succeed (21). If successful, the treat-
ment reduces the risk of progression to
vision loss by 90% (3).
The data supplied by Royal Devon
and Exeter did not include a way of
tracking disease progression rates. There-
fore, the progression of diabetic retinop-
athy was modeled using data from the
literature. We conducted an extensive
search of papers published after the Wis-
consin Epidemiologic Study of Diabetic
Retinopathy (12), upon which the POST
study was based (1,11), to see if there had
been any newer, but similar, large-scale
cohort studies that drew from a wide di-
abetic population and looked at the pro-
gression of diabetic retinopathy. We
found the closest match to be a cohort
study of diabetic patients in Melbourne
(13), in which baseline checks were per-
formed between 1992 and 1994, with
follow-up checks performed 5 years later.
Over 5 years, the probability of progres-
sion from no retinopathy to background
retinopathy was 0.096, from background
to preproliferative retinopathy was 0.187,
from preproliferative to proliferative reti-
nopathy was 0.25, and from proliferative
retinopathy to vision loss was 0.22. Daily
probabilities of progression were esti-
mated from the 5-year progression data
of the study. The Melbourne cohort
included a 22.6% prevalence of insulin-
treated diabetic patients and a higher
mean hemoglobin A1c (HbA1c), a poten-
tial indication of poor diabetes control, in
people who progressed to retinopathy
(13). The progression rates used in this
study therefore implicitly include those
patients who are at higher risk of devel-
oping diabetic retinopathy (13).
The maculopathy model
Diabetic maculopathy is a form of retinop-
athy that is common in the elderly and
typically occurs after BDR has developed
(11). Patients are screened formaculopathy
in their retinopathy screening sessions, as
patients can develop combinations of ret-
inopathy and diabetic macular edema
(DMO) or clinically significant macular
edema (CSMO) (11) in conjunction with
their diabetes. Of all patients in the Royal
Devon andExeter data, 8.5%were recorded
ashaving some formofdiabeticmaculopathy
(grade M1 of the U.K. National Screening
Committee grading system) (5).
To minimize complexity in ReSS, and
because our focus was on the diabetic
retinopathy complication, which more
commonly causes blindness and affected
more patients than maculopathy in the
Royal Devon and Exeter dataset, we did
not include a simulation of the progression
ofmaculopathy inReSS.However, to ensure
that the results obtained from ReSS would
remain applicable even when considering
patients who develop maculopathy, we de-
veloped a small spreadsheet model using
Microsoft Excel that includes maculopathy
and calculates the expected number of
patients in each possible stage of disease
progression for each year in a 15-year
period.
Unlike ReSS, the maculopathy com-
parison model only simulates the progres-
sion of patients’ diabetes complications
and does not consider screening, as this
requires a more complex modeling frame-
work, such as that used for ReSS. However,
this is not problematic, because we were
simply seeking to assess howmaculopathy
progression rates affect the proportion of
patients that lose their vision.
Maculopathy can occur at any stage
of progression of diabetic retinopathy
(11) and therefore cannot be simulated
using a single linear disease progression
path. Instead, we took into account all of
the possible permutations of retinopathy
and maculopathy (both DMO and CSMO
severities) and modeled each potential
route of progression as a separate “path.”
Specifically, a diabetic patient can de-
velop retinopathy and/or maculopathy
in any one of seven different ways (Table 1),
each of which can be considered a path of
progression of the disease (11).
For each path, a population of 5,000
type 2 diabetic patients was modeled over
a period of 15 years. We used progression
rates from the POST study (1,11) to deter-
mine the predicted number of patients
at each stage in the path in each year. All
patients start without retinopathy or
maculopathy (R0M0) in the maculopathy
comparisonmodel, no patients die for sim-
ple comparison between paths, and, for
simplification and to mimic a cohort-style
study, no newpatients are added over time.
RESULTSdThe proportion of type 2
diabetic patients in the ReSS model who
are predicted to lose their vision within 15
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years is 1.9% (60.1 SD) and is identical
under both scenarios (Fig. 2).
Over 15 years, the proposed new
screening policy (the 3S scenario) is pre-
dicted to incur £1,360,516 (6£10,036
SD) in costs for screening type 2 diabetic
patients, compared with £1,834,060
(6£21,286 SD) with the current screen-
ing policy (the 2S scenario) (Fig. 3). This
represents a 25.8% reduction in screening
costs if type 2 diabetic patients without
retinopathy are screened every 2 years in-
stead of annually. Furthermore, ReSS
predicts that only 12,561 screening ap-
pointments (6227 SD) would be carried
out for type 2 diabetic patients without ret-
inopathy over 15 years under the new
screening policy, comparedwith 23,611 ap-
pointments (6454 SD) under the existing
policy, a reduction of 11,050 appointments
over 15 years or 737 appointments per year.
In general, we found that the results
were insensitive to variations in all of the
key parameter values, with the exception
of progression rates of retinopathy. Un-
surprisingly, here the outputs were highly
sensitive to variation and gave vision loss
percentages ranging from 0.71 to 5.71%
of the population when halving and
doubling the implemented progression
rates, respectively. The Melbourne study
does report a significantly lower incidence
of new retinopathy diagnosis than other
studies (13) but points out that the reti-
nopathy progression rates were similar
to other studies (within a maximum of
11% variation), including the Wisconsin
Epidemiologic Study of Diabetic Retinop-
athy (12). We are therefore confident that
the progression rates reported by the
Melbourne study and used to parameterize
our model are sufficiently representative.
Of all the permutations tested in the
maculopathy comparisonmodel, thehighest
percentage of patients who are predicted
to lose their visionwithin 15 years is 1.2%,
which refers to patients who develop both
DMO and CSMO in the background
stages of retinopathy (path F). This com-
pares to 2.1% of patients for the group that
never develops maculopathy, only retinop-
athy (path A).
When building any model, it is vital
to extensively verify and validate it to
maximize the reliability of the predictions
that it generates. Verification is the pro-
cess of checking that the model performs
as expected by the design and that it is free
of errors, whereas validation checks that
the model produces the kind of behavior
and outputs that would be expected. Both
models correctly produced the expected
results for each of 29 tests.
CONCLUSIONSdOur model pre-
dicts that it is safe to screen type 2 diabetic
patients who have not been diagnosed
with retinopathy every 2 years, rather
than annually, because the proportion of
patients who develop retinopathy-mediated
vision loss is unaffected. Furthermore,
such a policy could reduce the cost of
screening by ;25%, thereby mitigating
the problem of increased demand on
screening services arising from significant
increases in diabetic prevalence. The pro-
portion of patients developing vision loss
remains the same under the new policy
because retinopathy progresses slowly,
and a screening interval of 2 years is suf-
ficiently frequent to identify patients at or
before the proliferative stage, where treat-
ment can be given.
By increasing the screening interval for
patients without retinopathy, it is possible
that early stages of retinopathy will be
diagnosed later. However, even if a patient
progresses through one or two stages of
retinopathy in the 2-year interval, they will
be screened more frequently once this is
identified. It is unlikely that a lower-risk
patient would progress from no retinopa-
thy to the proliferative stage within a 2-year
period, given the slow rate of progress of
the disease for many patients.
The proportion of patients who lose
their visionwhen consideringmaculopathy
complicationsnever exceeds thatof thepop-
ulation that never develops maculopathy.
Therefore, the 2-year screening interval
predicted to be safe by ReSS would not be
problematic for these patients.
Although the predictions generated
by ReSS are compelling, it is prudent to
Table 1dProgression paths in the maculopathy comparison model
Path ref Path description Comments
Path A R0→BDR→PDR→vision loss The path modeled by ReSS, simplified to
exclude preproliferative retinopathy (R2)
Path B R0→BDR→PDR→PDR+DMO→vision loss Vision loss from retinopathy
Path C R0→BDR→PDR→PDR+DMO→PDR+
CSMO→vision loss
Vision loss from maculopathy
Path D R0→BDR→BDR+DMO→PDR+
DMO→vision loss
Vision loss from retinopathy
Path E R0→BDR→BDR+DMO→PDR+
DMO→PDR + CSMO→vision loss




Vision loss from maculopathy
Path G R0→BDR→BDR+DMO→BDR+
CSMO→PDR+CSMO→vision loss
Vision loss from either retinopathy
or maculopathy
Path ref, each path has an arbitrary unique identifier.
Figure 2dProportion of type 2 diabetic patients who lost their vision. The figure shows the total
proportion of type 2 diabetic patients in themodel who lost their visionwithin the simulated period
of 15 years. Results are shown for both the current screening policy (2S) and the proposed three-
tier screening policy (3S). Results are averaged over 10 replications of the simulation.
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highlight potential caveats to a proposed
policy of 2-year screening intervals.
First, diabetic care is most effective
when individualized (22–24), and the
importance of retinal clinicians using
discretion on a case-by-case basis cannot
be overstated. Diabetic retinopathy has
been shown to be closely linked to indi-
vidual risk factors (25–28), and in some
cases such risks (longer duration of di-
abetes, poor metabolic control, or a dra-
matic change in glycemic levels) may
necessitate more frequent screening be-
cause of the potentially higher rates of
progression in these patients. Even if
these patients do not show signs of reti-
nopathy, more frequent screening may
be prudent due to the increased risk for
this subpopulation.
Second, there is concern that longer
screening intervals could lead to patients
misunderstanding the severity of reti-
nopathy or forgetting to attend screening
appointments (16). However, this is un-
likely to be problematic if a computerized
call-recall system is used to administer the
screening program, but could be explored
by comparing the impact of nonattendance
with the cost and resource benefits of a
2-year screening interval. Nevertheless, it
may be wise to ensure that any potential
screening interval changes are coupled
with a strategy of educating patients about
retinopathy and emphasizing the impor-
tance of good control in managing the di-
abetic condition.
Third, some of the key risk factors for
diabetic retinopathy, such as the level of
glycemic control and blood pressure, are
also associated with other nonocular
complications, such as nephropathy,
neuropathy, and strokes (2). More fre-
quent screening may be beneficial in
identifying such complications earlier,
although patients with diabetes would
continue to receive annual check-ups
for their condition even with a reduction
in retinopathy screening, and therefore
such risk factors could be identified at
these sessions.
Even with these caveats, the predic-
tions generated by the model certainly
present an appealing argument for ex-
tending the screening interval for diabetic
retinopathy in a subset of type 2 diabetic
patients. Although our study did not look
at linking patients’ clinical risk factors
with their recommended screening inter-
vals, our results imply that significant ben-
efits can be brought about simply by
reducing the screening interval for patients
who have not yet developed retinopathy.
Our predictions also support the findings
of other studies that have found longer
screening intervals for diabetic retinopathy
to be cost-effective (7,15,16). We would
therefore recommend a review of the cur-
rent NICE guidelines, which suggest an
annual retinopathy screening, atminimum,
for diabetic patients, as a way of addressing
the projected increased burden that will be
placed on NHS screening services without
increasing the risk of poor outcomes. In
addition, extensions to this research that
explicitly consider the impact of risk fac-
tors, such as through individualization
of screening intervals (29), may be benefi-
cial in assessing whether diabetic patients
who have developed retinopathy can also
be screened less frequently, depending on
their clinical assessment and control
of their condition.
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